Engineered Probiotic Bacteria Expressing Antimicrobial Peptide Fight E. coli Gut Infections in Mice
Freeze-dried engineered L. lactis expressing AMP HI reduced ETEC gut colonization, restored intestinal barrier, and suppressed inflammation in mice, demonstrating translational potential for engineered probiotic AMPs.
Quick Facts
What This Study Found
L. lactis/HI: optimized freeze-drying (6% sorbitol), reduced ETEC colonization and LPS, restored tight junction genes, downregulated TNF-α/IL-1β/IL-6, upregulated IL-10 in ETEC-infected mouse intestine.
Key Numbers
How They Did This
Engineering of L. lactis to express AMP HI, freeze-drying optimization with cryoprotectants, oral administration in ETEC-infected BALB/c mice, with colonization, LPS, tight junction, and cytokine assessment.
Why This Research Matters
Oral AMP delivery via engineered probiotics solves the stability/delivery problem — the probiotic produces the antibiotic exactly where the infection is.
The Bigger Picture
Engineered probiotics delivering AMPs could become a new class of oral anti-infectives that work locally in the gut without systemic side effects.
What This Study Doesn't Tell Us
Mouse model. ETEC is one pathogen; activity against others not tested. Regulatory pathway for engineered probiotics complex.
Questions This Raises
- ?Could engineered probiotic AMPs replace oral antibiotics for gut infections?
- ?How long does AMP expression persist after oral probiotic dosing?
- ?Would this approach work against C. difficile infection?
Trust & Context
- Key Stat:
- Living antibiotic factory Engineered probiotic bacteria produce antimicrobial peptide directly in the gut, fighting infection where antibiotics often fail to reach
- Evidence Grade:
- Preclinical proof-of-concept with translational freeze-drying optimization. Novel engineered probiotic AMP approach.
- Study Age:
- Published in 2025.
- Original Title:
- Engineered Lactococcus lactis expressing antimicrobial peptide HI: Enhanced survival and protection against ETEC in mice.
- Published In:
- Journal of biotechnology, 410, 331-340 (2026)
- Authors:
- Hu, Mingyang, Bi, Chongpeng(3), Li, Yuwen, Xue, Yutong, Cha, Sina, Zhao, Lu, Xue, Chenyu, Dong, Na
- Database ID:
- RPEP-15317
Evidence Hierarchy
Frequently Asked Questions
What is an engineered probiotic AMP?
A beneficial gut bacterium (L. lactis) genetically modified to produce antimicrobial peptides. When swallowed, it colonizes the gut and produces antibiotics exactly where infection occurs.
Is this better than regular antibiotics?
Potentially for gut infections. Regular antibiotics destroy beneficial bacteria system-wide. Engineered probiotics produce AMPs locally in the gut while maintaining the beneficial microbiome.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-15317APA
Hu, Mingyang; Bi, Chongpeng; Li, Yuwen; Xue, Yutong; Cha, Sina; Zhao, Lu; Xue, Chenyu; Dong, Na. (2026). Engineered Lactococcus lactis expressing antimicrobial peptide HI: Enhanced survival and protection against ETEC in mice.. Journal of biotechnology, 410, 331-340. https://doi.org/10.1016/j.jbiotec.2025.12.019
MLA
Hu, Mingyang, et al. "Engineered Lactococcus lactis expressing antimicrobial peptide HI: Enhanced survival and protection against ETEC in mice.." Journal of biotechnology, 2026. https://doi.org/10.1016/j.jbiotec.2025.12.019
RethinkPeptides
RethinkPeptides Research Database. "Engineered Lactococcus lactis expressing antimicrobial pepti..." RPEP-15317. Retrieved from https://rethinkpeptides.com/research/hu-2026-engineered-lactococcus-lactis-expressing
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.